OMPI Key Stats
- OBAGI MEDICAL PRODUCTS, INC. Files SEC form 8-K, Completion of Acquisition or Di... Apr 26
- Valeant completes tender offer for Obagi Medical Apr 25
- Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Med... Apr 25
- Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From t... Apr 24
- 4 Healthcare Stock Stories Prescribed for Investors Apr 23
- Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previ... Apr 23
- Valeant Receives Antitrust Clearance for Obagi Purchase Apr 22
- Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United S... Apr 22
- Gabelli raises stake in Obagi Medical to 12.17% from 11.14% Apr 17
- [video] The Five Dumbest Things on Wall Street: April 12 Apr 12
OMPI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Obagi Medical Products is up 87.49% over the last year vs S&P 500 Total Return up 27.95%, Cadence Pharmaceuticals up 140.1%, and ARCA biopharma down 3.01%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for OMPI
Pro Report PDF for OMPI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download OMPI Pro Report PDF
Pro Strategies Featuring OMPI
Did Obagi Medical Products make it into our Pro Portfolio Strategies?